{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T09:33:48Z","timestamp":1773740028021,"version":"3.50.1"},"reference-count":11,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2026,2,18]]},"DOI":"10.1136\/gutjnl-2026-338554","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:20:29Z","timestamp":1772216429000},"page":"gutjnl-2026-338554","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Time-varying dynamics of hepatic steatosis and cardiometabolic risk: implications for posthepatitis C cure HCC risk"],"prefix":"10.1136","author":[{"given":"Yu-Ping","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch Hsin-Chu Hospital, Hsinchu, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Chu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3622-9707","authenticated-orcid":false,"given":"Chen-Hua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan"},{"name":"Hepatitis Research Center, National Taiwan University Hospital, Taipei City, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"2026022710201900000_gutjnl-2026-338554v1.1","doi-asserted-by":"crossref","unstructured":"Chang Y-P , Chen Y-C , Cheng P-N , et al . Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease. Gut 2026.:gutjnl-2025-337275. doi:10.1136\/gutjnl-2025-337275","DOI":"10.1136\/gutjnl-2025-337275"},{"key":"2026022710201900000_gutjnl-2026-338554v1.2","doi-asserted-by":"crossref","unstructured":"Bhanushali M , Bhagat N , De A , et al . Metabolic determinants of hepatocellular carcinoma after SVR: persisting uncertainties. Gut 2026;gutjnl\u20132026:gutjnl-2026-338377. doi:10.1136\/gutjnl-2026-338377","DOI":"10.1136\/gutjnl-2026-338377"},{"key":"2026022710201900000_gutjnl-2026-338554v1.3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(20)30357-5","article-title":"Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis","volume":"6","author":"Petroff","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026022710201900000_gutjnl-2026-338554v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.12.022"},{"key":"2026022710201900000_gutjnl-2026-338554v1.5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-26293-9","article-title":"Eradication of hepatitis C virus is associated with the attenuation of steatosis as evaluated using a controlled attenuation parameter","volume":"8","author":"Shimizu","year":"2018","journal-title":"Sci Rep"},{"key":"2026022710201900000_gutjnl-2026-338554v1.6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00535-024-02101-2","article-title":"Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals","volume":"59","author":"Liu","year":"2024","journal-title":"J Gastroenterol"},{"key":"2026022710201900000_gutjnl-2026-338554v1.7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jhep.2024.09.038","article-title":"Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection","volume":"82","author":"Liu","year":"2025","journal-title":"J Hepatol"},{"key":"2026022710201900000_gutjnl-2026-338554v1.8","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000843"},{"key":"2026022710201900000_gutjnl-2026-338554v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.11.040"},{"key":"2026022710201900000_gutjnl-2026-338554v1.10","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/apt.70029","article-title":"Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral-Induced Cure of Hepatitis C Virus Infection","volume":"61","author":"Chang","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"2026022710201900000_gutjnl-2026-338554v1.11","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/cid\/ciz304","article-title":"Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES)","volume":"70","author":"Butt","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2026-338554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T18:20:30Z","timestamp":1772216430000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2026-338554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":11,"alternative-id":["10.1136\/gutjnl-2026-338554"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2026-338554","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]}}}